EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Century Therapeutics's Enterprise Value is $330.7 Mil.
Century Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-95.5 Mil. Therefore, Century Therapeutics's EV-to-FCF for today is -3.46.
The historical rank and industry rank for Century Therapeutics's EV-to-FCF or its related term are showing as below:
IPSC'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.33 Med: -0.25 Max: 3.22
Current: -3.46
During the past 7 years, the highest EV-to-FCF of Century Therapeutics was 3.22. The lowest was -13.33. And the median was -0.25.
IPSC's EV-to-FCF is ranked worse than 100% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs IPSC: -3.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Century Therapeutics (NAS:IPSC) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Century Therapeutics's PE Ratio (TTM) for today is calculated as:
Century Therapeutics's share price for today is $2.315.
Century Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Century Therapeutics EV-to-FCF Related Terms
Century Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Century Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Century Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's EV-to-FCF falls into.
Century Therapeutics's current Enterprise Value is $330.7 Mil.
Century Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-95.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics (IPSC) has a EV-to-FCF of -3.46 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Century Therapeutics and its competitors. According to the industry distribution chart, Century Therapeutics ranks #999999 out of 327 companies in the Biotechnology industry.
Is Century Therapeutics' EV-to-FCF too high?
Century Therapeutics' current EV-to-FCF is -3.46. Based on the distribution chart, Century Therapeutics ranks #999999 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' EV-to-FCF compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #999999 out of 327 companies for EV-to-FCF. This places Century Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Century Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Century Therapeutics's current EV-to-FCF is -3.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.32 — trading 94.1% below its estimated fair value. The current EV-to-FCF is -3.46. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current EV-to-FCF is -3.46 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.32 is trading 94.1% below its estimated GF Value™ of $38.91.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
EV-to-FCF: -3.46
GF Value™: $38.91 vs. price of $2.32 (94.1% below fair value)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
